NCT07075471Recruiting

MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Deciphera Pharmaceuticals, LLC

Start Date

9/3/2025

Completion Date

9/1/2027

Summary

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: 1. Diagnosis of TGCT according to medical records 2. Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated. 3. Has provided informed consent and medical records release Exclusion Criteria: 1\. Participant is active in an interventional clinical trial of vimseltinib

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Tenosynovial Giant Cell Tumor

Locations

Synexus Clinical Research, US INC

Wilmington, North Carolina 28401

United States